Alzamend Neuro (NASDAQ:ALZN) Shares Up 14.2%

Alzamend Neuro, Inc. (NASDAQ:ALZN)’s stock price shot up 14.2% on Friday . The stock traded as high as $1.75 and last traded at $1.69. 52,491 shares changed hands during trading, an increase of 241% from the average session volume of 15,391 shares. The stock had previously closed at $1.48.

Alzamend Neuro Stock Performance

The firm has a market cap of $10.93 million, a price-to-earnings ratio of -0.70 and a beta of 0.14. The company’s fifty day moving average is $3.24 and its two-hundred day moving average is $5.90.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Wednesday, September 13th. The company reported ($0.60) EPS for the quarter.

Hedge Funds Weigh In On Alzamend Neuro

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in Alzamend Neuro in the 4th quarter worth $28,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Alzamend Neuro in the 4th quarter valued at about $30,000. HRT Financial LP acquired a new stake in shares of Alzamend Neuro in the 4th quarter valued at about $32,000. Virtu Financial LLC acquired a new stake in shares of Alzamend Neuro in the 4th quarter valued at about $35,000. Finally, Bank of America Corp DE acquired a new stake in shares of Alzamend Neuro in the 1st quarter valued at about $35,000. Institutional investors and hedge funds own 6.37% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.